CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)

Size: px
Start display at page:

Download "CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)"

Transcription

1

2

3

4 CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)

5 Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.

6 INDIANA CP-CRE CASES, Total: 355 Total: 294 Total: Cases Average: Month *Preliminary 2018 data represents 1/1/2018 5/31/2018

7 INDIANA CP-CRE CASES BY DISTRICT, State: 802 District 1: 358 District 2: 29 District 3: 62 District 4: 18 District 5: 176 District 6: 86 District 7: 40 District 8: 16 District 9: 17 District 10: 0 *Preliminary 2018 data represents 1/1/2018 5/31/2018

8 INDIANA CP-CRE CASES, CP-CRE cases ORGANISMS 621 KLEBSIELLA PNEUMONIAE 55 SERRATIA MARCESCENS MECHANISMS 44 ESCHERICHIA COLI 740 KPC 36 ENTEROBACTER CLOACAE COMPLEX 18 NDM 18 CITROBACTER FREUNDII COMPLEX 15 VIM 14 KLEBSIELLA OXYTOCA 9 OXA-48-LIKE 6 CITROBACTER KOSERI 20 UNKNOWN 3 PROTEUS MIRABILIS 2 KLEBSIELLA AEROGENES 1 PROVIDENCIA RETTGERI 1 LECLERCIA ADECARBOXYLATA 1 MORGANELLA MORGANII *Preliminary 2018 data represents 1/1/2018 5/31/2018

9 1. 2. Most bacteria have 1 or 2 mechanisms of resistance. P. aeruginosa & Acinetobacter use ALL FOUR!

10 CRE Carbapenemase Producing (CP-CRE) Multiple Mechanisms KPC NDM VIM OXA SME IMI Porin Enzyme Efflux Ceftaz/avibactam Meropenem/ vaborbactam Polymixins Aztreonam Aztreonam PLUS Ceftaz/avibactam Polymixins

11 VICIOUS CYCLE Fluoroquinolones ES Cephalosporins ESBLs Tigecycline, Colistin Nursing Home LTAC Hemodialysis Carbapenem Use Carbapenemase

12 The selection of the optimal antimicrobial drug regimen, including dose, route, and duration of therapy Right Drug Right Dose Right Diagnosis Antimicrobial Stewardship Right Duration Barlam, TF et al. Guideline for Implementing an Antibiotic Stewardship Program, CID 2016

13 Leadership Commitment Hospital administration supports efforts to improve antimicrobial use Accountability Identify a single leader responsible for program outcomes Training in AMS Drug Expertise Identify a pharmacist to co-lead Action Develop interventions or policies to improve antibiotic use Tracking & Reporting Monitor prescribing patterns Report on antimicrobial use, patient outcomes, and resistance patterns Education Educate staff and patients about resistance and optimal prescribing CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2014

14 AMS TEAM ID MD* ID PharmD* Information Technologist Infection Preventionist Patient Quality Improvement Clinicians Nurses Laboratory *Recommended to have specific training/expertise in antimicrobial stewardship

15 Formulary Management Education Combat the Emergence of Resistance Guidelines & Order Sets Dose Optimization Antimicrobial Stewardship De-escalation Length of Therapy Selection of Antimicrobial Control Costs Diagnosis Dellit TH. Clin Infect Dis 2007;44(2): Lawrence KL, et al. Am J Respir Crit Care Med 2009;179: Improve Clinical Outcomes Rapid Diagnostics & Microbiology IV to PO

16

17

18

19

20 3 days 7 days 10 days 14 days days 28 days days Chastre J, et al. JAMA 2003; 290:

21 STUDY DETAILS STUDY DESIGN OUTCOMES Stamm WE, et al. Acute renal infection in women: Treatment with TMP-SMX or Ampicillin for 2 or 6 Weeks Prospective, randomized trial 2 weeks of treatment was as efficacious as 6 weeks of treatment Longer duration was less well tolerated (more adverse effects) Longer duration was associated with increased recurrence (20% for 2 weeks and 36% for 6 weeks) Published 1987 Included 60 patients Treatment groups: Ampicillin PO or TMP/SMX PO Duration: 2 or 6 weeks Gupta K, et al. Clin Infect Dis 2011; 52(5): e103-e120. Stamm WE, et al. Ann Intern Med 1987; 106: 341.

22 Days of IV Vancomycin Therapy vs. VRE Infection Risk days days 5.4 >7 days None Also saw increased risk of VRE infection with use of fluoroquinolones and meropenem Antibiotics may drive resistance outside of their own class Gouliouris T et al. Duration of exposure of multiple antibiotics is associated with increased risk of VRE bacteremia: a nested case-control study. J Antimicrob Chemother 2018;73:

23

24 LARGE IMPACT

25 Redefining the Antibiotic Stewardship Team: Recommendations from the American Nurses Association/Centers for Disease Control and Prevention Workgroup on the Role of Registered Nurses in Hospital Antibiotic Stewardship Practices CDC

26

27 If the answer is yes to all these questions, discussion about switching to oral antibiotics is appropriate

28 Early Switch Therapy Moderate to severe PNA LOS -3.34days 95%CI -4.42, Adverse events OR %CI 0.48, 0.89 No difference in treatment success OR %CI 0.61, 1.39 No difference in Recurrence OR %CI 0.7, 4.72 No difference in Mortality OR %CI 0.49, 1.33 CAP (Meta of 3 studies) Mean LOS -3.04days 95%CI -4.9 to Mandel LA, et al. CID 2007;44(suppl 2):S27-72.

29

30

31 ARE CULTURES REALLY THAT IMPORTANT TO ANTIMICROBIAL STEWARDSHIP? 31

32 IMPACT OF CULTURE RESULTS Need to Treat or Not Treat Drive Order Sets / Empiric Treatments Impact Quality Metrics (ie. CAUTI) Drug Selection Influence Drug Formulary Decisions Antibiotic Resistance Dose Selection Annual Antibiogram Report Patient Outcomes Duration of Treatment Isolation Precautions Cost of Care 32

33 WHY IS TECHNIQUE IMPORTANT? NEITHER REQUIRE ANTIBIOTICS! Normal Flora of the Skin Staphylococci (Coagulase-negative) Staphylococcus aureus Diphtheroids (corynebacterium) Streptococci sp. 33

34 KEYS TO SUCCESS 34

35 SWABS & SENDING SPECIMENS 35 (Adapted from Perry AG, et al. [2014]. Clinical nursing skills & techniques [8th ed]. St. Louis: Mosby.)

36 Microbiology Workflow Blood Drawn t=0 Gram Stain t=8 h Samples Plated for Sub-culture t=24-36h Resistance Testing Culture Results t=48-72h

37 COST OF MICROBIOLOGY LAB WORK-UP Deep wound culture performed $387* $900* 37 *Cost does not include tech time

38

39 ~10% 95% of patients report a penicillin allergy are not allergic Sacco KA. Allergy 2017; 72:

40 40 Vancomycin Cefazolin % Patients Treatment Failure(1) Mortality (2) 1. Stryjewski ME. Clin Infect Dis.2007;44: Kim S. Antimicrob Agents Chemother.2008;52(1):

41 Study Details Study Design Results Clin Infect Dis 2016;63(7): Prospective, cohort study conducted on the ID service at 3 academic hospitals N=507 patients 95 (19%) had β-lactam allergies Beta-lactam was preferred therapy in 72 (76%) J Allergy Clin Immunol 2014;133: Retrospective, matched cohort study of patients admitted to Kaiser Foundation Hospitals 51,582 unique subjects with PCN allergy were casematched with 2 controls When β-lactam preferred, 25 (35%) did not receive preferred treatment, despite 13 (52%) reported as non-severe reactions Patients who did not receive preferred βlactam therapy had greater risk of adverse events (aor, 3.1; 95% CI, ) vs those w/o allergy Patients receiving preferred β-lactam therapy had similar risk of adverse events vs those w/o allergy (aor, 1.33; 95% CI, ) Cases w/ PCN allergy averaged 0.59 (9.9%; 95% ci, ) more hospital days vs controls Cases were treated w/ more FQs, clindamycin, and vancomycin (P<0.0001) vs controls Cases had 23.4% (95% CI, 15.6% to 31.7%) more C.difficile, 14.1% (95% CI, 7.1% to 2`.6%) more MRSA, and 30.1% (95% CI, 12.5% to 50.4%) more VRE vs controls

42 Urticaria/Hives Wheezing Shortness of Breath Angioedema Anaphylaxis Stephen s Johnson Syndrome N/V (Intolerance) Headache (Intolerance) Diarrhea (Intolerance) Family History (not a true allergy) Known side effects of medications Additional Questions: How long ago was the reaction? What antibiotics have they tolerated since?

43 Odds Ratio of Receiving Carbapenem AMS intervention Prior B-lactam PCN allergy Al-Hasan, MN, et al.pharmacotherap.2018,38(1):

44

45 MINIMUM INHIBITORY CONCENTRATION OR MIC S I R

46 Concentration Cmax:MIC AUC:MIC T>MIC MIC 0 Time (hours) AUC = Area under the concentration time curve Cmax = Maximum plasma concentration

47 Drug Time>MIC Susceptible (µg/ml) Piperacillin/ tazobactam 16 Ceftriaxone 1 Cefepime 8 Meropenem P. aeruginosa Peak:MIC Enterobacteriaceae 2 1 Tobramycin 4 Ciprofloxacin 1

48 Susceptible (µg/ml) Peak Serum Concentration (µg/ml) Piperacillin/ tazobactam Ceftriaxone Cefepime Drug Time>MIC Fluoroquinolone Meropenem P. aeruginosa Peak:MIC Selection PCN Aminoglycoside BS PCN 1-2 Cephalosporin 3-4 Cephalosporin Carbapenem 25 Enterobacteriaceae 2 1 Tobramycin 4 21 Ciprofloxacin 1 3.6

49

50 Exposure & Colonization Disruption of intestinal flora Inadequate host immune response Spore transmission McFarland, LV. J Med Microbiol 2005;54: CDI

51

52 Burdette SD, et al. Clin Infect Dis 2007; 44(8): Antimicrobial Resistance Solutions, Inc. ALL RIGHTS RESERVED

53

54

55

56

57 Days of Antibiotic Therapy vs. Adjusted CDI Hazard Ratio <4 days Reference Stevens V et al. CID 2011;53(1): days 95% CI 0.8, days 95% CI 1.9, >18 days 95% CI 4.6, drug Reference drugs 95% CI 1.6, drugs 95% CI 2.2, drugs 95% CI 6.1, 15.1 Number of Antibiotics vs. Adjusted CDI Hazard Ratio

58 Antibiotic CDI Adjusted Hazard Ratio (95% CI) Fluoroquinolones 4.0 (2.7, 5.9) Aminoglycosides 0.9 (0.3, 3.0) Clindamycin 1.9 (0.8, 4.4) 3 rd /4 th Generation Cephalosporins 3.1 (1.9, 5.2) Stevens V et al. CID 2011;53(1):42-48.

59

60

61

62

63

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

Antimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD

Antimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

Antimicrobial Stewardship:

Antimicrobial Stewardship: Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of

More information

Infection Control of Emerging Diseases

Infection Control of Emerging Diseases 2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event

More information

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services 2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens

More information

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital 2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects

More information

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant

More information

Antimicrobial Pharmacodynamics

Antimicrobial Pharmacodynamics Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they

More information

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO) Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health

More information

Fighting MDR Pathogens in the ICU

Fighting MDR Pathogens in the ICU Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Preventing the Spread of Antibiotic Resistance and Improving Patient Care (Adapted from the Centers for Disease Control and Prevention) What is Stewardship? Antimicrobial stewardship

More information

C&W Three-Year Cumulative Antibiogram January 2013 December 2015

C&W Three-Year Cumulative Antibiogram January 2013 December 2015 C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...

More information

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital 2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....

More information

Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE

Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE Crisis: Antibiotic Resistance Success Strategy WWW.optimistic-care.org

More information

Antimicrobial Stewardship 101

Antimicrobial Stewardship 101 Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential

More information

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.

More information

Preventing and Responding to Antibiotic Resistant Infections in New Hampshire

Preventing and Responding to Antibiotic Resistant Infections in New Hampshire Preventing and Responding to Antibiotic Resistant Infections in New Hampshire Benjamin P. Chan, MD, MPH NH Dept. of Health & Human Services Division of Public Health Services May 23, 2017 To bring a greater

More information

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases 4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome

More information

Witchcraft for Gram negatives

Witchcraft for Gram negatives Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

Antibiotic Stewardship in the LTC Setting

Antibiotic Stewardship in the LTC Setting Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

Mono- versus Bitherapy for Management of HAP/VAP in the ICU

Mono- versus Bitherapy for Management of HAP/VAP in the ICU Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,

More information

Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim

Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim Program/Project Description, including Goals What was the problem to be solved? How was it identified? What baseline data existed?

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

SHC Clinical Pathway: HAP/VAP Flowchart

SHC Clinical Pathway: HAP/VAP Flowchart SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal

More information

Cost high. acceptable. worst. best. acceptable. Cost low

Cost high. acceptable. worst. best. acceptable. Cost low Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy

More information

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical

More information

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015 Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New

More information

Breaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester

Breaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships

More information

LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES

LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present

More information

It s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings. Emily Heil, PharmD, BCPS-AQ ID, AAHIVP

It s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings. Emily Heil, PharmD, BCPS-AQ ID, AAHIVP It s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings Emily Heil, PharmD, BCPS-AQ ID, AAHIVP Conflict of Interest I have no conflicts of interest to disclose related to the content

More information

Antimicrobial Stewardship Program 2 nd Quarter

Antimicrobial Stewardship Program 2 nd Quarter Antimicrobial Stewardship Program 2 nd Quarter May 19, 2016 Jill Hanson, WHA DeAnn Richards, MetaStar Objectives for Today Hospital Highlight UnityPoint Health - Meriter Status of the state Update on pilot

More information

Antimicrobial Cycling. Donald E Low University of Toronto

Antimicrobial Cycling. Donald E Low University of Toronto Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms

Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Nimalie D. Stone, MD,MS Division of Healthcare Quality Promotion National

More information

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control

More information

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Int.J.Curr.Microbiol.App.Sci (2017) 6(3):

Int.J.Curr.Microbiol.App.Sci (2017) 6(3): International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are

More information

Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data

Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Trevor Van Schooneveld MD, Scott Bergman, PharmD, BCPS, Paul Fey, PhD, Mark Rupp, MD The Clinical Microbiology laboratory

More information

Multi-drug resistant microorganisms

Multi-drug resistant microorganisms Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018 Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?

More information

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and

More information

CF WELL Pharmacology: Microbiology & Antibiotics

CF WELL Pharmacology: Microbiology & Antibiotics CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure

More information

Antimicrobial Stewardship Program

Antimicrobial Stewardship Program Antimicrobial Stewardship Program David R. Woodard, MSc, FSHEA, CIC CDC: Antibiotic Resistance Threats in the United States, 2013 http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ CDC Threat Levels

More information

Leveraging the Lab and Microbiology Department to Optimize Stewardship

Leveraging the Lab and Microbiology Department to Optimize Stewardship Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center

More information

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse

More information

Antimicrobial susceptibility

Antimicrobial susceptibility Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL

More information

Antimicrobial Stewardship Advisory Committee Meeting

Antimicrobial Stewardship Advisory Committee Meeting Antimicrobial Stewardship Advisory Committee Meeting August 25, 2016 3:00 PM-4:30 PM Washington State Dept of Health Room A42 1610 NE 150th St Shoreline, WA 98155 Call in: (571) 317-3116 Access Code: 211-449-029

More information

Best Practices: Goals of Antimicrobial Stewardship

Best Practices: Goals of Antimicrobial Stewardship Best Practices: Goals of Antimicrobial Stewardship Gail Scully, M.D, M.P.H. and Elizabeth Radigan, PharmD, BCPS UMass Memorial Medical Center Division of Infectious Disease Department of Medicine September

More information

The Rise of Antibiotic Resistance: Is It Too Late?

The Rise of Antibiotic Resistance: Is It Too Late? The Rise of Antibiotic Resistance: Is It Too Late? Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine None DISCLOSURES THE PROBLEM Antibiotic resistance is one of the

More information

Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship

Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Background Why Antimicrobial Stewardship 30-50% of antibiotic use in hospitals are unnecessary or inappropriate Appropriate antimicrobial use is a medication-safety and patient-safety

More information

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;

More information

Collecting and Interpreting Stewardship Data: Breakout Session

Collecting and Interpreting Stewardship Data: Breakout Session Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline

More information

Sustaining an Antimicrobial Stewardship

Sustaining an Antimicrobial Stewardship Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial

More information

Microbiology Basics and Applications to Clinical Practice

Microbiology Basics and Applications to Clinical Practice Microbiology Basics and Applications to Clinical Practice LINDSEY CHILDS-KEAN, PHARMD, MPH, BCPS CLINICAL ASSISTANT PROFESSOR UNIVERSITY OF FLORIDA COLLEGE OF PHARMACY ST. PETERSBURG, FL Disclosures I

More information

Rise of Resistance: From MRSA to CRE

Rise of Resistance: From MRSA to CRE Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance

More information

New Drugs for Bad Bugs- Statewide Antibiogram

New Drugs for Bad Bugs- Statewide Antibiogram New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda

More information

Antibiotic Stewardship: The Facility Role and Implementation. Tim Cozad, LPN, Lead LTC Health Facilities Surveyor

Antibiotic Stewardship: The Facility Role and Implementation. Tim Cozad, LPN, Lead LTC Health Facilities Surveyor Antibiotic Stewardship: The Facility Role and Implementation Tim Cozad, LPN, Lead LTC Health Facilities Surveyor Phase II CMS Regulatory Changes Current information available includes: New Survey Process

More information

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection

More information

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1 Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director

More information

Using Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and

Using Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and Using Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and Health-Care Associated Infections Overall Goals & Objectives:

More information

2015 Antimicrobial Susceptibility Report

2015 Antimicrobial Susceptibility Report Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf

More information

Jump Starting Antimicrobial Stewardship

Jump Starting Antimicrobial Stewardship Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing

More information

RCH antibiotic susceptibility data

RCH antibiotic susceptibility data RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological

More information

Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care

Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Jennifer McCann, PharmD, BCCCP State Director of Clinical Pharmacy Services St. Vincent Health Indiana Conflicts of Interest No

More information

Antimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance

Antimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance Antimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance Natalie Weber, PharmD PGY2 Critical Care Pharmacy Resident September 22, 2016 The speaker has no actual or potential conflicts of

More information

Geriatric Mental Health Partnership

Geriatric Mental Health Partnership Geriatric Mental Health Partnership September 8, 2017 First, let s test your knowledge about antibiotics http://www.cdc.gov/getsmart/community/about/quiz.html 2 Get Smart Antibiotics Quiz Antibiotics fight

More information

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the

More information

ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014

ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 Olga Perovic, 1,2 Verushka Chetty 1 & Samantha Iyaloo 1 1 National Institute for Communicable Diseases, NHLS 2 Department

More information

Antimicrobial Stewardship Basics Why, What, Who, and How. Philip Chung, PharmD, MS, BCPS ASAP Community Network Pharmacy Coordinator October 12, 2017

Antimicrobial Stewardship Basics Why, What, Who, and How. Philip Chung, PharmD, MS, BCPS ASAP Community Network Pharmacy Coordinator October 12, 2017 Antimicrobial Stewardship Basics Why, What, Who, and How Philip Chung, PharmD, MS, BCPS ASAP Community Network Pharmacy Coordinator October 12, 2017 Objectives List reasons for developing antimicrobial

More information

ADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao

ADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao ADC 216 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao Willemstad, November 217 Authors: Radjin Steingrover clinical microbiologist, head dpt. Microbiology ADC

More information

Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL

Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital

More information

Optimizing Selection of Empirical Antimicrobial Therapy in the Era of Precision Medicine

Optimizing Selection of Empirical Antimicrobial Therapy in the Era of Precision Medicine Optimizing Selection of Empirical Antimicrobial Therapy in the Era of Precision Medicine Majdi Al-Hasan, MBBS Associate Professor of Medicine University of South Carolina School of Medicine Disclosure

More information

Antibiotic Stewardship in the Hospital Setting

Antibiotic Stewardship in the Hospital Setting Antibiotic Stewardship in the Hospital Setting G. Evans, MD FRCPC Medical Director, Infection Prevention & Control Kingston General Hospital & Hotel Dieu Hospital EOPIC September 26, 2012 Stewardship stew-ard-ship

More information

Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler

Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations

More information

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Highlights for the Medical Staff Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Standard Precautions every patient every time a. Hand Hygiene b. Use of Personal Protective Equipment (PPE)

More information

Bad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016

Bad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016 Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose

More information